Biblio
Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022.
. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023;7(16):4371-4380.
Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016.
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023.
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021;5(13):2753-2759.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
Prognostic significance of stringent complete response post stem cell transplantation in AL amyloidosis. Biol Blood Marrow Transplant. 2018.